PapersPMID:35490461
Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study.
- findings
- 3
- compound
- 1
- endpoints
- 3
- no difference found
- 1
- Study, every finding
- RCT · 17 days
- Dose studied, every finding
- inulin increased from 4 g/d to 8 g/d to 16 g/d over 17 days, against maltodextrin placebo on the same schedule
What moved
How to read these marks →“Linear regression analysis revealed that the levels of AST and ALT at T2 were higher in the inulin group than in the placebo group (Linear regression models β = 8.55, 95% CI [2.33; 14.77], p = 0.008 and β = 6.01, 95% CI [2.02; 10.00] p = 0.004 respectively; Table 3).”
- Population
- Adults with alcohol use disorder hospitalised for a 3-week alcohol detoxification program, whole sample; adjusted for sex, ethanol consumed in week 2 and the baseline value; measured at day 19 after 17 days of supplementation
- Population
- Adults with alcohol use disorder hospitalised for a 3-week alcohol detoxification program, whole sample; adjusted for sex, ethanol consumed in week 2 and the baseline value; measured at day 19 after 17 days of supplementation
What did not
“No difference was observed for abdominal pain, bloating, stool frequency, the total score of gastrointestinal tolerance or the creatinine level between placebo and inulin group at the end of the study.”
- Population
- Adults with alcohol use disorder hospitalised for a 3-week alcohol detoxification program, whole sample; safety endpoint at the end of 17 days of supplementation
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Patients with alcohol use disorder (DSM-5) hospitalised for a 3-week detoxification programme; whole sample plus an exploratory subgroup with early alcohol-associated liver disease (eALD); inulin is Fibruline
- Participants
- 50
- Comparator
- placebo
- Duration
- 17 days
- Endpoints measured
- 79